Valirx plc (LSE:VAL) has announced the creation of a wholly owned subsidiary, Valirx Animal Health Ltd, marking a strategic expansion into the rapidly growing animal health sector while maintaining its core focus on oncology drug development.
Speaking on The Watchlist, Valirx CEO Mark Eccleston explained that the move is designed to complement the company’s existing human therapeutics pipeline while opening new commercial and research opportunities in veterinary medicine.
A Growing Market Opportunity
The global animal health market is experiencing steady growth and is projected to reach approximately $5 billion by 2030 in the oncology segment alone, comparable in size to the triple-negative breast cancer market, one of Valirx’s key targets in human medicine.
Eccleston said the opportunity lays in developing treatments that can benefit both animals and humans.
“Comparative oncology allows us to develop drugs for animals in animals, but the research also benefits the human market,” he said. “It’s essentially a parallel development stream.”
Comparative oncology studies naturally occurring cancers in animals, particularly dogs, to generate insights that may accelerate human drug development. Because many cancers in dogs behave similarly to those in humans, the approach can provide valuable data on treatment response, safety, and disease biology.
Complementing the Human Oncology Pipeline
Valirx has historically focused on oncology drug development and asset partnering. According to Eccleston, the creation of the animal health subsidiary is not a shift in strategy but rather an extension of a model the company has long considered.
He noted that ValiRx’s first spin out, Volition, has had success in veterinary diagnostics with a point of care canine cancer screening test which was ultimately sold for $28 million, before the equivalent human diagnostic was fully developed.
“Animal health offers faster access to markets and lower regulatory barriers,” Eccleston explained. “It allows us to potentially bring clinical products to market more quickly, generating revenue while supporting our human research.”
The biological similarities between cancers in dogs and humans mean data gathered in veterinary trials can also strengthen the human drug development pathway.
“All the safety testing and profiling work done in the canine side complements what happens on the human side,” he added.
Hub-and-Spoke Investment Model
The new subsidiary also fits into Valirx’s broader corporate structure, which Eccleston described as a “hub and spoke” model.
Under this structure, Valirx acts as the central hub while individual assets are placed into special purpose vehicles (SPVs). These SPVs can attract targeted investment while remaining linked to the parent company.
Valirx Animal Health will operate as a dedicated veterinary SPV, with oncology assets from other divisions potentially cross-licensed into the subsidiary.
This model provides flexibility for investors.
“If you want to invest in the main company, you can,” Eccleston said. “But if you want to focus on a specific asset or the veterinary medicine market, this structure opens those opportunities.”
The approach could also create additional funding pathways for the company by allowing external investors to participate directly in individual programs or sectors.
Outlook for the Next Two Years
Over the next 12 to 24 months, Valirx expects the animal health division to play a key role in expanding optionality across its portfolio. By combining human oncology research with veterinary applications, the company aims to accelerate development timelines, attract new investment, and unlock additional value from its intellectual property.
While the company’s primary identity remains rooted in human oncology innovation, the launch of Valirx Animal Health signals a broader ambition: leveraging comparative oncology to advance treatments for both humans and animals.
For more information on Valirx visit – https://valirx.com/
Leave a Reply